Pharmaceuticals, Biotechnology and Life Sciences
Abivax said Thursday that ABX464 inhibits replication of SARS-CoV-2 in an in vitro reconstituted human respiratory epithelium model, as assessed by Transepithelial electrical resistance and RTqPCR.
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
Novavax said Monday that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-CoV-2.
Sterling Pharma has announced a partnership with Accord Healthcare to secure the UK supply chain for Hydroxychloroquine (HCQ), a medication currently under investigation for the prevention and treatment of COVID-19.
Researchers at The Lundquist Institute began Thursday a randomized, double-blind, placebo-controlled clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in individuals suffering from COVID-19
Certara is applying expertise in clinical pharmacology, innovation and collaboration to accelerate potential prophylaxis for COVID-19.
Moderna has engaged with Lonza to work on its novel coronavirus vaccine, with a goal to enable manufacturing of up to 1 billion doses per year, noting that technology transfer is expected to begin in June 2020.
MigVax is getting an investment of $12 million to accelerate path to clinical trials and bring Israel’s human coronavirus vaccine to market, as it pioneers the effort to develop Israel’s human vaccine against COVID-19.
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.